
    
      The trial is an open-label, multi-center safety trial of GEN1046. The trial consists of two
      parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase
      2a)). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose
      (RP2D) has been determined.
    
  